View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 2, 2020

Gilead’s remdesivir gets MHRA green light, but only targets a select group of Covid-19 patients

By Victoria Smith

Last week, Gilead’s remdesivir received its first positive scientific opinion from the Medicines and Healthcare products Regulatory Agency (MHRA) under the Early Access to Medicines Scheme (EAMS) for use in Covid-19 patients.

GlobalData suspects that remdesivir will target a select severity group of Covid-19 patients, with the question of how it will be best to initiate and optimise treatment of the disease with the drug. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology